Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of GenMark Diagnostics Inc (NASDAQ: GNMK) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of GenMark Diagnostics Inc (NASDAQ: GNMK) concerning whether a series of statements by GenMark Diagnostics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On November 2, 2017, GenMark revealed that revenue recognition for expected placements of the Company's ePlex product was slowed by a longer-than-expected customer evaluation and validation process prior to implementation of ePlex in routine clinical use. 

Following this news, NASDAQ: GNMK fell as much as $2.63, or 36.23%, during intraday trading on November 3, 2017.

Based in Carlsbad, California, GenMark Diagnostics Inc develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology.

If you purchased shares of GenMark Diagnostics Inc (NASDAQ: GNMK) on or before November 2, 2017, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185